Twenty individual counties in Arkansas brought this civil suit against Pfizer, Inc., PDK Labs, Inc., Warner Lambert Company, LLC, Johnson & Johnson, Perrigo Company, and various John Does (collectively “Defendants”), 1 each of whom manu *663 factures or distributes products containing ephedrine or pseudoephedrine. The complaint sought compensation to recoup the costs expended by the counties in dealing with the societal effects of the methamphetamine epidemic in Arkansas, with liability premised on the use of the Defendants’ products in the methamphetamine manufacturing process. Sixteen of the counties (collectively “Counties”) appeal the district court’s 2 order granting the Defendants’ motion for judgment on the pleadings under Rule 12(c) of the Federal Rules of Civil Procedure, and we affirm.
I.
Because we are reviewing a judgment granted on the pleadings, we view all the facts pleaded by the Counties, the nonmovants, as true, and we make all reasonable inferences in the Counties’ favor.
Poehl v. Countrywide Home Loans, Inc.,
The Defendants are manufacturers and distributors of over-the-counter cold and allergy medications containing either ephedrine or pseudoephedrine. None of the Defendants are retailers, nor do they sell the medications directly to the public. The Counties allege that the Defendants marketed and sold their products in Arkansas knowing that the products were being used illegally to manufacture methamphetamine. 3 The Counties allege that the Defendants knew that their products were being used illegally at least as early as 1986 when the federal Drug Enforcement Administration (DEA) began pushing for controls over the sale of products containing ephedrine or pseudoephedrine. During two different time periods, in 1995-1996 and in 1998-1999, the DEA placed restrictions on the importation of bulk ephedrine and tracked the sales of ephedrine and pseudoephedrine outside of “blis *664 ter packs.” According to the Counties, methamphetamine use and abuse declined dramatically during these time periods, but the Defendants allegedly fought to create loopholes in the regulations to continue reaping large profits in the sale of their products. In time, the Counties say, methamphetamine cooks learned how to exploit the loopholes, and methamphetamine use rose again.
The Counties claim that the Defendants knew of measures they could have voluntarily taken to reduce the availability of their products to methamphetamine cooks but consciously chose not to, fighting regulatory efforts in order to continue reaping large profits. The actions that the Defendants (who are manufacturers and wholesalers) allegedly should have voluntarily taken included directing the retailers to place the products behind the counter of retail stores; requiring the retailers to make retail purchasers sign for products when purchased from the retailer; educating the retailers and their employees about suspicious behavior by persons seeking to purchase the products for illegal use; requiring the retailers to lock the products in display cases; and requiring the retailers to limit the amount of product that could be purchased at retail by an individual during a specified period of time. These measures were eventually included in DEA regulations issued in 2005. The Counties also alleged that two of the Defendants, Warner Lambert and Pfizer, developed effective alternative cold medications that did not contain ephedrine or pseudoephed-rine and that could not be used to produce methamphetamine, but that neither of them brought the alternative products to market.
The Counties assert that the Defendants knew they were selling far more than the legitimate market for their products consumed as evidenced by the fact that the revenues of one of the Defendants, Perri-go, declined rapidly from $182 million to $30 million once regulations were passed in 2005 limiting access to the Defendants’ products. The Counties also allege that the DEA sent letters to some of the Defendants warning them that their products were being used to make methamphetamine and that an executive from Pfizer admitted that the pharmaceutical industry was responsible for a portion of the methamphetamine problem in the United States. The Counties do not allege, however, that any of the Defendants violated any federal or state regulation governing the manufacture, distribution, packaging, or sale of their products. Nor do the Counties dispute that the sale of products containing ephedrine and pseudoephedrine is heavily regulated by both state and federal agencies.
The Counties sought damages under four different causes of action: common law unjust enrichment; the Arkansas Deceptive and Unconscionable Trade Practices Act (ADTPA), see Ark Code Ann. § 4-88-107; common law nuisance; and the Arkansas crime victims civil liability statute, see Ark.Code Ann. § 16-118-107. The District Court granted the Defendants’ motion for judgment on the pleadings, 4 and the Counties appeal.
*665 II.
The Counties filed their case in Arkansas state court, and the Defendants removed it to federal court based on diversity of citizenship. 28 U.S.C. § 1332. We therefore apply federal procedural rules,
see Scenic Holding, LLC v. New Bd. of Trustees of Tabernacle Missionary Baptist Church, Inc.,
Our task in this diversity case is to apply Arkansas law and, where an issue has not been decided by the Supreme Court of Arkansas, to predict how it would decide the issue.
See STL 300 N. 4th, LLC v. Value St. Louis Assocs., L.P.,
A. Unjust Enrichment
The Counties claim that the Defendants were unjustly enriched -at the Counties’ expense when methamphetamine cooks purchased the Defendants’ products for use in the illegal manufacture of methamphetamine. Unjust enrichment is an equitable doctrine that allows a party to recover for benefits conferred on another. It is restitutionary in nature and focuses on the benefit received.
See Dews v. Halliburton Indus., Inc.,
The Counties believe they have stated a claim for unjust enrichment by establishing that the Defendants were enriched by selling their products, that the enrichment was unjust because the sales allegedly violated the law and public policy of Arkansas related to manufacturing methamphetamine, and that the Counties are entitled to compensation related to services provided in dealing with the methamphetamine epidemic. Unjust enrichment is based on an implied contract theory of recovery, however, and Arkansas courts “will only imply a promise to pay for services where they were rendered in such circumstances as authorized the party performing them to entertain a reasonable expectation of their payment by the party beneficiary.”
Dews,
B. Nuisance and, Statutory Claims— Proximate Cause
The remaining three causes of action asserted by the Counties include common law nuisance, liability for violating the ADTPA, and liability under Arkansas’s crime victims civil liability statute. To state a cause of action for nuisance in Arkansas, the “the nuisance must ... be the natural and proximate cause of the injury.”
Taylor Bay Protective Ass’n v. Adm’r, U.S. E.P.A.,
In Arkansas, proximate cause is “defined as ‘that which in a natural and continuous sequence, unbroken by any efficient intervening cause, produced the injury, and without which the result would not have occurred.’ ”
City of Caddo Valley v. George,
Arkansas common law incorporates the doctrine of intervening acts, which reflects the limits that society places on a defendant’s liability for his actions. An “ ‘original act ... is ... eliminated as a proximate cause by an intervening cause [if] the latter is of itself sufficient to stand as the cause of the injury,’ ” and the intervening act is “
‘totally independent
’ ” of the original act.
City of Caddo Valley,
The original act alleged here is the Defendant manufacturers’ sales of cold medicine containing pseudoephedrine to retail establishments, with the knowledge that methamphetamine cooks purchase the cold medicine (or obtain it illegally) from the retailers and use it to manufacture methamphetamine, combined with the Defendants’ refusal to implement measures to
*668
limit access to their products for illegal use. The intervening causes asserted by the Defendants include: the conduct of the independent retailers in selling the products; the illegal conduct of methamphetamine cooks purchasing the cold medicine along with numerous other items with the intent to manufacture methamphetamine; the illegal conduct of cooking the items into methamphetamine; and the illegal conduct of distributing the methamphetamine to others in Arkansas. The alleged injury is the cost to the Counties of providing government services to deal with the methamphetamine epidemic in Arkansas: expenditures related to law enforcement, inmate housing, treatment, and family services. The question then is whether the intervening causes are the natural and probable consequences of the Defendants’ sales of cold medicine to retail stores and whether the Counties’ expenditures for government services to deal with the methamphetamine epidemic “might reasonably have been foreseen [to the cold medication manufacturers] as probable.”
Shannon,
The Counties assert that the district court erred in dismissing the suit on the pleadings, arguing that but for the Defendants’ sale of cold medicine containing pseudoephedrine, the cooks could not have made methamphetamine in such large quantities, and the Counties would not have needed to provide additional government services to deal with the methamphetamine-related problems. Although this line of reasoning may arguably satisfy the cause in fact prong of proximate cause, it does not address the separate issue of legal causation. Arkansas courts have dismissed actions on the pleadings based on a lack of proximate cause where the facts fail to meet the legal causation standard. In
Hartsock v. Forsgren, Inc.,
We have located no published decisions from any jurisdiction addressing a pharmaceutical manufacturer’s civil liability for government services stemming from the use of pseudoephedrine to manufacture methamphetamine where liability is premised on the manufacturer’s sale of products containing pseudoephedrine through legal retail channels. The liability that the Counties attempt to impose on the manufacturers in this case is analogous, however, to cases seeking to impose liability on gun manufacturers for government services provided to address the hazards of illegally possessed guns.
In one analogous gun case, the Third Circuit held that under Pennsylvania law, a city could not maintain an action for public nuisance or negligence against a gun manufacturer to recover for the city’s costs in combating crime involving the ille
*669
gal use or possession of guns.
See City of Philadelphia v. Beretta U.S.A. Corp.,
The allegations in the Third Circuit case are nearly identical to the allegations here — that the Defendant manufacturers failed to take steps to restrict access to the products containing pseudoephedrine when they knew (an alleged fact we take as true at the judgment on the pleadings stage) that the pseudoephedrine-containing products were being purchased and used illegally to make methamphetamine. Critical to the Third Circuit’s analysis was the “long and tortuous” route the guns took from the manufacturers, who complied with the law in selling the guns, to the streets of Philadelphia.
City of Philadelphia,
We recognize that not all jurisdictions to address the liability of gun manufacturers have taken the same approach as the Third Circuit of dismissing cases at the pleading stage.
See Camden County Bd. of Chosen Freeholders v. Beretta, U.S.A. Corp.,
Although these cases rely on the lack of a duty owed to support a tort claim, they are instructive on the issue of proximate cause. There is a “link between the questions of the existence of a duty and the existence of legal cause” because “[b]oth depend on an analysis of foreseeability.”
City of Chicago v. Beretta U.S.A. Corp.,
The criminal actions of the methamphetamine cooks and those further down the illegal line of manufacturing and distributing methamphetamine are “sufficient to stand as the cause of the injury” to the Counties in the form of increased government services, and they are “totally independent” of the Defendants’ actions of selling cold medicine to retail stores,
City of Caddo Valley,
As in the analogous gun cases, “[t]he Count[ies] make[] no allegation that any manufacturer violated any federal or state statute or regulation governing the manufacture and distribution of [pseudoephed-rine], and no direct link is alleged between any manufacturer and any specific criminal act.”
Camden County Bd. of Chosen Freeholders,
Proximate cause is bottomed on public policy as a limitation on how far society is willing to extend liability for a defendant’s actions. As a federal court construing state law, we are very reluctant to open Pandora’s box to the avalanche of actions that would follow if we found this case to state a cause of action under Arkansas law. We could easily predict that the next lawsuit would be against farmers’ cooperatives for not telling their farmer customers to sufficiently safeguard then-anhydrous ammonia (another ingredient in illicit methamphetamine manufacture) tanks from theft by methamphetamine cooks. And what of the liability of manufacturers in other industries that, if stretched far enough, can be linked to other societal problems? Proximate cause seems an appropriate avenue for limiting
*672
liability in this context, as in the gun manufacturer context, particularly “where an effect may be a proliferation of lawsuits not merely against these defendants but against other types of commercial enterprises — manufacturers, say, of liquor, antidepressants, SUVs, or violent video games — in order to address a myriad of societal problems regardless of the distance between the ‘causes’ of the ‘problems’ and their alleged consequences.”
Beretta, U.S.A., Corp.,
The Counties assert that this situation is different from the gun cases from other jurisdictions based on two unique Arkansas statutes: the Drug Dealer Liability Act, Ark.Code Ann. § 16-124-101 to § 16-124-112, and the crime victims civil liability statute, id. § 16-118-107, which allegedly set this case apart from analogous cases brought under common law theories of liability. Neither of these statutes convinces us that the Arkansas courts would extend civil liability as a matter of public policy to the pharmaceutical manufacturers in this case. The Drug Dealer Liability Act is premised on “damages caused by use of an illegal drug by an individual,” § 16-124-104(a), with the individual drug user being critical to the Act’s provisions, see id. § 16-124-104(a)(4) (granting a cause of action to a “governmental entity ... that funds a drug treatment program ... for the individual drug user or that otherwise expended money on behalf of the individual drug user ” (emphasis added)); § 16-124-102(4) (defining “individual drug user” as “the individual whose illegal drug use is the basis for an action brought under this chapter”). The Counties’ assertion that this Act establishes a public policy holding manufacturers of products containing pseudoephedrine liable for societal costs, as opposed to costs related to individual drug users, is unavailing.
Arkansas’s crime victims civil liability statute fares no better. That statute provides a civil cause of action to “[a]ny person injured or damaged by reason of conduct of another person that would constitute a felony under Arkansas law.” Ark.Code Ann. § 16-118-107(a)(l). The Counties claim that the Defendants’ actions constitute the felony of selling or distributing a product containing ephedrine or pseudoephedrine “with reckless disregard as to how the product will be used.” See Ark.Code Ann. § 5-64-1102(b)(1)(B). Subsection (b) was added to § 5-64-1102 in 2001, see 2001 Ark. Acts, Act 1209, § 4, by the same Act in which the Arkansas legislature added § 5-64-1103, see 2001 Ark. Acts, Act 1209, § 5, limiting retail sales of products containing pseudoephedrine to no more than three packages. Thus, at the same time that the Defendant manufacturers allegedly became subject to criminal liability based on their reckless disregard for how their products were being used, those same products could be sold by retailers in very limited quantities (one of the measures the Counties asserted the Defendants should have taken voluntarily). The Counties do not allege that the retailers to whom the Defendant manufacturers sold their cold medications failed to comply with this statute, or any other statute or regulation governing the sale of products containing pseudoephed- *673 rine. Given the Arkansas legislature’s focus on curtailing the availability of products from legitimate retail sources, we cannot agree with the Counties that Arkansas courts would extend civil liability to manufacturers who sell their pseu-doephedrine-containing products to independent retailers, who in turn are limited in their sales of the products. In any event, as previously discussed, the statutory civil cause of action includes an element of proximate cause, which we have found lacking as a matter of law.
The Counties cite no case, federal or state, that recognizes a cause of action available to a government entity to recover against pharmaceutical manufacturers for the legal sale of products containing pseu-doephedrine based on the subsequent use of the product in the manufacture of methamphetamine. “[I]t is not the role of a federal court to expand state law in ways not foreshadowed by state precedent,”
City of Philadelphia,
III.
Given the current state of the law in Arkansas, we affirm the district court’s judgment.
Notes
. The original complaint filed in Arkansas state court also named American Novelties; Cliff McQuay, Cliff McQuay, Jr. and Ellen McQuay, d/b/a/ Cliff McQuay Sales Company; and Jr. Food Mart of Arkansas, Inc. as defendants. These defendants were severed from *663 the case when it was removed to federal court, and they were neither parties to the case in district court, nor are they parties to this appeal.
. The Honorable William R. Wilson, United States District Judge for the Eastern District of Arkansas.
. In their briefs to this court, the Counties allege that the Defendants intentionally targeted methamphetamine cooks by printing "pseudoephedrine” on the outside packaging of their cold medicines. These allegations were not included in the complaint, by which we are constrained in reviewing this dismissal on the pleadings. In any event, the Counties do not dispute that the packaging complied with the federal Food and Drug Administration regulations.
. We reject the Counties’ claim that the district court inappropriately applied the summary judgment standard rather than the standard applicable to a judgment on the pleadings. Although the one-page Judgment referred to the Defendants' Motion for Summary Judgment, the 13-page Order correctly identified the motion as a Motion for Judgment on the Pleadings. Upon a careful review of the Order, we are satisfied that the district court properly limited its consideration to the facts alleged in the pleadings and correctly applied the standard applicable to a Rule 12(c) motion.
. The allegation made in the briefs that the manufacturers marketed the products to the methamphetamine cooks by placing the word "pseudoephedrine” prominently on the packaging does not change the analysis. The products were still sold to independent retailers, and these alleged marketing methods did not change the fact that the methamphetamine cooks still had to obtain the products through the retailers.
See Lorcin,
